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Approaches to screening for active tuberculosis (TB) among people living with HIV are inad-
equate, leading to missed diagnoses and poor implementation of preventive therapy.
Methods
Consecutive HIV-infected adults hospitalized at Mulago Hospital (Kampala, Uganda)
between June 2011 and July 2013 with a cough� 2 weeks were enrolled. Patients under-
went extensive evaluation for pulmonary TB. Concentrations of 43 cytokines/chemokines
were measured at the same time point as C-reactive protein (CRP) in banked plasma sam-
ples using commercially-available multiplex kits. Advanced classification algorithms were
used to rank cytokines/chemokines for their ability to identify TB, and to model the specificity
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of the top-ranked cytokines/chemokines individually and in combination with sensitivity con-
strained to� 90% as recommended for TB screening.
Results
The median plasma level of 5 biomarkers (IL-6, INF-γ, MIG, CRP, IL-18) was significantly
different between patients with and without TB. With sensitivity constrained to 90%, all had
low specificity with IL-6 showing the highest specificity (44%; 95% CI 37.4–49.5). Biomarker
panels were found to be more valuable than any biomarker alone. A panel combining IFN-γ
and IL-6 had the highest specificity (50%; 95% CI 46.7–53.3). Sensitivity remained high
(>85%) for all panels among sputum smear-negative TB patients.
Conclusions
Direct measurement of unstimulated plasma cytokines/chemokines in peripheral blood is a
promising approach to TB screening. Cytokine/chemokine panels retained high sensitivity
for smear-negative TB and achieved improved specificity compared to individual cytokines/
chemokines. These markers should be further evaluated in outpatient settings where most
TB screening occurs and where other illnesses associated with systematic inflammation are
less common.
Introduction
Tuberculosis (TB) now ranks as the most common infectious disease cause of death and
accounts for approximately one third of all deaths in people living with HIV (PLHIV) [1, 2].
To combat this deadly co-infection, the World Health Organization (WHO) articulated the "3
I’s" strategy for reducing the burden of TB among PLHIV [3]. Key parts of this strategy include
intensified case finding (ICF) consisting of screening all PLHIV for active TB at every health-
care encounter, followed by isoniazid preventative therapy (IPT) for those who screen negative
and diagnostic testing for those who screen positive [4, 5]. However, the uptake and efficiency
of IPT and ICF are limited by the lack of a TB screening test that has high enough sensitivity to
rule-out TB for patients who test negative—thereby facilitating IPT initiation—and moderate
specificity to identify a smaller subset of patients who require confirmatory TB diagnostic test-
ing, thereby facilitating ICF.
Currently, the WHO recommends TB screening be performed using a four-part symptom
screen alone or in conjunction with chest radiography (CXR) for PLHIV in high burden set-
tings [5, 6]. Although the symptom screen has high sensitivity, recent data indicate that nearly
all PLHIV are symptom screen-positive, particularly in sub-Saharan Africa [6–14]. The addi-
tion of CXR improves specificity, but cost and infrastructure requirements make implementa-
tion difficult at many HIV/AIDS clinics [6, 11, 14–16]. Thus, TB screening currently results in
few PLHIV being identified as candidates for IPT and the vast majority requiring confirmatory
testing. For these reasons, a low-cost and accurate screening test that can be performed by
front-line health workers has been ranked among the highest priority needs for TB diagnostics
[17, 18].
Measurement of inflammatory markers, cytokines and chemokines holds promise for facili-
tating TB screening [19, 20]. Previous studies have analyzed the accuracy of individual inflam-
matory markers such as C-reactive protein (CRP) and cytokines/chemokines such as
interferon gamma (INF-γ), interferon gamma-induced protein (IP-10), monokine induced by
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interferon-γ (MIG), interleukin 6 (IL-6), and interleukin 18 (IL-18) for diagnosing active TB
[21–27]. Of these, CRP has shown the most promise as a potential TB screening tool with high
(89%) sensitivity for active TB and variable specificity (generally higher among outpatients
and lower among hospitalized patients) [10, 22, 28–31]. We hypothesized that a panel of
inflammatory markers, cytokines and/or chemokines measured directly in blood samples
would have higher diagnostic accuracy for TB than CRP alone. To test this hypothesis, we
measured levels of CRP and 43 cytokines/chemokines in stored plasma samples from an inpa-
tient cohort of HIV-infected adults with presumptive pulmonary TB.
Methods
Study population and setting
We analyzed stored plasma samples from consecutive HIV-infected adults enrolled between
June 2011 and July 2013 in an ongoing study, the International HIV-associated Opportunistic
Pneumonias (IHOP) Study, of patients admitted to Mulago Hospital in Kampala, Uganda with
cough for�2 weeks. Mulago Hospital is the national referral hospital in Uganda. As part of the
parent study, patients submitted two sputum samples for acid-fast bacilli (AFB) smear micros-
copy (LED fluorescence microscopy) and liquid mycobacterial culture (MGIT), and one sample
for GeneXpert MTB/RIF testing [32, 33]. Patients were followed-up two months after enroll-
ment to assess for clinical improvement and repeat microbiologic assessment for TB if symp-
toms had not improved. Blood samples were collected in EDTA anti-coagulant at the time of
enrollment and plasma was stored at -80 degrees Celsius. For this study, we included consecu-
tive HIV-infected adult patients who 1) did not have a prior history of TB; 2) had sufficient spu-
tum culture results to assess the reference standard (see Outcome Definition below); and 3) had
a stored plasma sample available for analysis. The parent study (IHOP) was approved by institu-
tional review boards at the University of California San Francisco and Makerere University, and
by the Uganda National Council for Science and Technology. Informed written consent was
obtained for participants at the time of their original enrollment as part of the IHOP studies. As
this study represents a secondary analysis from that cohort, additional informed consent was
not required. All data and samples were obtained and stored according to protocols approved
by the Committee on Human Research at the University of California San Francisco, the School
of Medicine Research Ethics Committee at Makerere University (Kampala, Uganda), and the
Uganda National Council for Science and Technology.
Multiplex cytokine/chemokine analysis
Two separate multiplex panels were used to measure a total of 43 cytokines/chemokines in
plasma samples from 74 patients that had undergone only a single freeze-thaw cycle to mini-
mize degradation. Samples were stored for approximately three years at -70 C prior to analysis.
One kit included 41 cytokines/chemokines (EMD Millipore, Billerica, MA): Soluble CD40
ligand (sCD40L), vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF)-α,
TNF-β, transforming growth factor (TGF)-α, chemokine ligand 5/RANTES (CCL5), platelet-
derived growth factor (PDGF)-AB/BB, PDGF-AA, macrophage inflammatory protein (MIP)-
1β, MIP-1α, macrophage-derived chemokine (MDC), monocyte chemotactic protein (MCP)-
1, MCP-3, interleukin (IL)-17, IL-15, IL-13, IL-12 (p70), IL-12 (p40), IL-10, IL-9, IL-8, IL-7,
IL-6, IL-5, IL-4, IL-3, IL-2, IL-1ra, IL-1β, IL-1α, IFN-γ, IFN-α2, IP-10, growth-related onco-
gene (GRO), granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte-col-
ony stimulating factor (G-CSF), fractalkine, Fms-related tyrosine kinase 3 (Flt-3) ligand,
fibroblast growth factor (FGF)-2, eotaxin, and epidermal growth factor (EGF). The second kit
(Bio-Rad, Hercules, CA) included 2 cytokines/chemokines: monokine induced by interferon-γ
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(MIG) and IL-18 [21]. Based on initial results (See Results: Biomarker Selection), 6 cytokines/
chemokines were selected for further evaluation in 262 patients using custom-ordered multi-
plex kits: IFN-γ, IL-6, GRO, MDC (EMD Millipore, Billerica, MA), and IL-18 and MIG (Bio-
Rad, Hercules, CA). The multiplex analysis was performed in duplicate on all samples accord-
ing to the manufacturer’s recommendations at the Center for Comparative Medicine Labora-
tory, University of California, Davis. In addition to cytokines/chemokines levels (pg/ml), CRP
levels (mg/L) were measured on a second aliquot of plasma in the Zuckerberg San Francisco
General Hospital (ZSFG) Chemistry Laboratory by a turbidimetric method using a Beckman
Coulter Analyzer. Technicians measuring cytokine/chemokine levels and CRP levels were
blinded to clinical data including TB status. Patients were excluded from the data analysis if
there was insufficient plasma to perform CRP measurement, results of duplicate biomarker
measurements were not available, or the coefficient of variation was >0.3 between duplicate
measurements.
Outcome definition
We classified patients as having TB if sputum mycobacterial culture results were positive and
speciation testing confirmed Mycobacterium tuberculosis complex, or if culture results were
negative but both AFB smear and GeneXpert MTB/RIF results were positive. We classified
patients as not having TB if all microbiologic testing for TB–including at least two liquid cul-
ture results–was negative and patients either had clinical improvement without anti-TB ther-
apy or an alternate diagnosis established by the 2-month follow-up visit.
Data analysis
We compared the differences in median biomarker responses between TB and non-TB patients
using the Mann-Whitney test. We performed random forest modeling using two-thirds of the
dataset to rank the relative variable importance of each biomarker in differentiating between TB
and non-TB patients based on a mean decrease in Gini impurity index, a measure of heteroge-
neity in a group. A greater decrease in Gini impurity index indicates better classification, thus
indicating a biomarker has greater relative importance [34, 35]. We subsequently built bio-
marker panels starting with the two top-ranked biomarkers based on variable importance and
including the next highest ranked biomarker one at a time. For each panel, we developed a pre-
diction algorithm for identifying TB using SuperLearner, a machine-learning ensemble that
compares different learners (prediction methods) using cross-validated risk [36, 37]. SuperLear-
ner builds a weighted linear combination of the included learners favoring those that minimize
mean squared error to return predictions on the dataset using cross-validation to prevent over-
fitting. For this analysis, we included logistic regression, Bayes’ generalized linear models, lasso,
random forest, and a null model (in order to assess relative performance with other methods) as
candidate learners [38–40]. After fitting the SuperLearner algorithm with two-thirds of the data-
set, we applied it to the entire dataset and used the predicted probabilities of TB obtained after
10-fold cross-validation to calculate sensitivity, specificity, and cross-validated area under the
curve (AUC), along with associated 95% confidence intervals (CI). For all biomarker panels, we
constrained sensitivity to be 90% or higher based on the WHO’s target product profile for a TB
screening test [7]. All analyses were performed using R, version 3.0.2.
Results
Of 865 patients enrolled in the parent study, 306 (35%) did not have a definite TB status, 111
(13%) had prior TB, and 10 (1%) had no stored sample. Data from the first 74 eligible patients
(66% of whom were culture-positive for TB) were used for biomarker selection only. Of the
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remaining 364 patients, 9 (2%) showed a coefficient of variation >0.3 for at least one cytokine/
chemokine, while 93 (25%) did not have CRP testing performed (Fig 1). Thus, 262 patients
were included in the main analysis. Among the 262 patients, 150 (57%) were female, median
age was 34 years (IQR 29–39), median CD4 count was 86 cells/μL (IQR 24–257), 65 (25%)
were on anti-retroviral therapy, and 43% had advanced illness confining them to bed rest for
at least part of each day. Of the included participants, 155 (59%) had culture-positive TB (68%
smear-positive and 32% smear-negative) and 107 (41%) were assessed to be TB-negative based
on microbiological evaluation and clinical follow-up. Of note, there were no significant differ-
ences in clinical or demographic characteristics among patients included and excluded from
the analysis (data not shown).
Biomarker selection (N = 74)
The median level (pg/ml) of 13 of 43 cytokines/chemokines measured was significantly differ-
ent between patients with (n = 49) and without (n = 25) TB (S1 Table). The median level of
CRP was also significantly higher in TB patients compared to patients without TB. Median
Fig 1. Patient selection. Of 865 patients enrolled in the parent study, 427 (49%) did not meet eligibility criteria, and 74
(9%) were included only for biomarker selection. Of the 364 patients eligible for the full study, 102 (28%) were
excluded from the analysis. Abbreviations: TB, tuberculosis; CRP, C-reactive protein.
https://doi.org/10.1371/journal.pone.0206119.g001
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levels were�2-fold higher among patients with TB than patients without TB for INF-γ, MIG,
IL-6, IL-18, and G-CSF and were�1.5-fold higher for CRP, IL-8, IP-10, GRO, SCD-40L, TNF-
α, and IL-1α. Results were similar when biomarkers were considered together and ranked by
variable importance (S2 Table). The median level of 6 of the top 10 biomarkers based on vari-
able importance (INF-γ, IL-18, CRP, IL-6, GRO, IP-10) was�1.5-fold higher among patients
with TB than patients without TB. Two of the biomarkers (MDC and IL-17) had levels that
were lower among patients with TB than patients without TB.
We selected the top 7 biomarkers (INF-γ, IL-18, CRP, IL-6, MDC, GRO, and IP-10) identified
as promising based on variable importance for further analysis based on feasibility considerations.
However, we replaced IP-10 with MIG for further analysis despite a lower variable importance
score because of the�2-fold difference in the medial level of MIG between patients with and
without TB, prior data demonstrating that MIG and IP-10 levels were highly correlated, and prior
data suggesting that IP-10 is more likely to degrade after long-term storage [21, 41].
Diagnostic accuracy (N = 262)
Among the remaining 262 patients, the median plasma level of 5 of the 7 selected biomarkers
(IL-6, INF-γ, MIG, CRP, IL-18) was significantly different between patients with and without
TB (Table 1). Median levels were�3-fold higher among TB patients for IL-6 and INF-γ,
�2-fold higher for MIG and CRP, and 1.9-fold higher for IL-18. When considered together,
the rank order from highest to lowest based on variable importance was IFN-γ, IL-6, MIG, IL-
18, CRP, MDC, and GRO (Table 1).
With sensitivity constrained to be at least 90%, all 7 individual biomarkers had low specific-
ity for active TB (S3 Table). IL-6 had the highest specificity (44%, 95% CI 37.4–49.5). In the
assessment of biomarker panels, with sensitivity constrained to 90%, specificity was higher
with the combination of IFN-γ and IL-6 (50%, 95% (CI 46.7–53.3) than for either biomarker
alone (Table 2). Adding the next top-ranked biomarker resulted in decreasing specificity, but
the specificity of all panels containing from 2 to 7 of the top-ranked biomarkers was higher
than that for the individual biomarkers included, except for IL-6. When applying TB risk cut-
off points obtained from the full dataset, sensitivity remained high (>85%) for all biomarker
panels among sputum smear-negative TB patients (Table 3).
Discussion
A simple, low-cost, and accurate TB screening test is a key priority for achieving global TB
elimination targets. In this study, we analyzed 44 blood biomarkers and identified at least five
Table 1. Variable importance and median concentrations (pg/ml) of 7 selected biomarkers (N = 262).
Biomarker Variable Importance Ranking No TB (n = 107) TB (n = 155) Fold Difference p-value
Median (IQR) Median (IQR)
IFN-γ 1 20 (11–34) 61 (36–126) 3.1 <0.001
IL-6 2 23 (13–50) 77 (40–130) 3.3 <0.001
MIG 3 2994 (1508–6425) 7741 (3346–13495) 2.6 <0.001
IL-18 4 248 (137–438) 482 (272–817) 1.9 <0.001
CRP (mg/l) 5 69 (23–158) 140 (78–209) 2.0 <0.001
MDC 6 788 (532–1169) 673 (518–925) 0.9 0.064
GRO 7 1390 (963–1931) 1432 (1111–1858) 1.0 0.738
Abbreviations: TB, tuberculosis; IQR, interquartile range, INF-γ, Interferon gamma; IL-6, Interleukin-6; MIG, Monokine induced by interferon-γ; IL-18, Interleukin-18;
CRP, C-reactive protein; MDC, Macrophage-derived chemokine; GRO, Growth-related oncogene.
https://doi.org/10.1371/journal.pone.0206119.t001
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(IFN-γ, IL-6, MIG, IL-18, and CRP) that showed potential for utility in TB screening. All five
biomarkers had levels that were>1.5-fold higher in TB patients than in patients without TB in
the pilot and full datasets, and were the top-ranked biomarkers by variable importance in the
full dataset. With sensitivity constrained to�90%, specificity was poor—as expected in an
inpatient cohort—for all individual biomarkers and for all biomarker panels. However, speci-
ficity was higher for biomarker panels than for individual biomarkers, including CRP. Combi-
nations of the biomarkers identified here should be further evaluated among ambulatory
PLHIV undergoing systematic screening for active TB.
Our data are consistent with previous studies that have evaluated blood biomarkers in the
context of TB diagnosis. Levels of IFN-γ, IL-6, MIG, and IL-18 have all been found to be higher
in patients with TB than in healthy controls [21], household contacts [23], or patients undergo-
ing TB evaluation who test negative [24, 26]. CRP has been more extensively evaluated. Sensi-
tivity has been consistently high while specificity has varied with the population being studied
(range 6–52% in inpatient studies and 58–81% in ambulatory screening studies [31]). Our
study is among the first to evaluate all five of these biomarkers, and the previous studies sup-
port that the biomarkers identified here can be expected to have higher specificity in the con-
text of TB screening in ambulatory settings, where patients without TB are less likely to have
other illnesses resulting in systemic inflammation.
In addition to the biomarkers identified here, others such as IP-10 have been reported
recently to have utility for differentiating patients with and without active TB. For example,
Table 2. Accuracy of biomarker panels with sensitivity constrained to 90% (N = 262).
Biomarker Panel Specificity (95% CI) cvAUC
IFN-γ, IL-6 50.4 (46.7–53.3) 0.844
IFN-γ, IL-6, MIG 48.3 (44.9–51.4) 0.830
IFN-γ, IL-6, MIG, IL-18 46.6 (43.0–49.5) 0.851
IFN-γ, IL-6, MIG, IL-18, CRP 40.3 (36.4–43.0) 0.825
IFN-γ, IL-6, MIG, IL-18, CRP, GRO 41.8 (37.4–45.8) 0.826
IFN-γ, IL-6, MIG, IL-18, CRP, GRO, MDC 40.3 (36.4–43.9) 0.836
Abbreviations: TB, tuberculosis; CI, confidence interval; cvAUC, cross-validated area under the receiver operator
curve; INF-γ, Interferon gamma; IL-6, Interleukin-6; MIG, Monokine induced by interferon-γ; IL-18, Interleukin-18;
CRP, C-reactive protein; MDC, Macrophage-derived chemokine; GRO, Growth-related oncogene.
https://doi.org/10.1371/journal.pone.0206119.t002
Table 3. Sensitivity of biomarker panels among sputum smear-positive vs. smear-negative TB patients.
Biomarker Panel Sensitivity (95% CI)
Smear-positive TB (N = 50) Smear-negative TB (N = 105)
IFN-γ, IL-6 91.3 (89.5–92.4) 85.7 (84.0–86.0)
IFN-γ, IL-6, MIG 91.7 (89.5–93.3) 85.5 (84.0–86.0)
IFN-γ, IL-6, MIG, IL-18 90.8 (89.5–92.4) 87.5 (84.0–92.0)
IFN-γ, IL-6, MIG, IL-18, CRP 91.5 (89.5–93.3) 88.2 (84.0–92.1)
IFN-γ, IL-6, MIG, IL-18, CRP, GRO 90.8 (89.5–92.4) 88.3 (82.0–94.0)
IFN-γ, IL-6, MIG, IL-18, CRP, GRO, MDC 91.1 (89.5–92.4) 88.1 (82.0–94.0)
Abbreviations: TB, tuberculosis; CI, confidence interval; INF-γ, Interferon gamma; IL-6, Interleukin-6; MIG,
Monokine induced by interferon-γ; IL-18, Interleukin-18; CRP, C-reactive protein; MDC, Macrophage-derived
chemokine; GRO, Growth-related oncogene.
https://doi.org/10.1371/journal.pone.0206119.t003
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Biraro et al found that IP-10 was able to differentiate patients with latent or active TB versus
those who were not infected [25] and Mihret et al found that IP-10 plasma levels could differ-
entiate between active TB patients and healthy household contacts [23]. Our study confirmed
these findings; however, we replaced IP-10 with MIG for analyses (See Biomarker Selection).
Due to the strong performance of IP-10 in our data and prior literature, it should be included
along with IFN-γ, IL-6, MIG, IL-18, and CRP in future studies of TB screening in ambulatory
populations.
Our study has several strengths, including a rigorous TB reference standard, robust statisti-
cal methods, and the use of unstimulated peripheral blood specimens in contrast to many bio-
marker studies that use stimulated specimens. However, the study also has several limitations.
First, the study population was not representative of the majority of patients who would
undergo TB screening due to the higher severity of illness and thus greater systemic inflamma-
tion in the TB-negative patients in this cohort. However, we successfully identified a smaller
number of biomarkers that can be further evaluated in future studies for TB screening in out-
patient settings. Second, samples from many patients were not included because TB status
could not be clearly defined. Additionally, patients who could not produce sputum were
excluded as their TB status could not be classified. However, symptoms and severity of illness
were similar among patients included and excluded from the analysis. Nonetheless, the large
number of exclusions introduces the potential for bias. Third, the plasma samples used in this
analysis had been stored for >2 years and some cytokines/chemokines could have degraded
more than others [41]. Last, even if validated in a screening cohort, point-of-care testing plat-
forms would need to be developed before panels of inflammatory markers could be used for
TB screening by frontline health workers in high-burden countries.
Conclusions
Direct measurement of a panel of inflammatory markers, cytokines, and chemokines in
peripheral blood is a promising approach to TB screening. Each of the biomarkers identified
in this study performed better than symptom-based screening, and performed better than
CRP alone when combined into panels. These biomarkers should be further evaluated in out-
patient settings where most TB screening occurs and where other illnesses associated with sys-
temic inflammation are less common in order to identify the optimal panel and to determine
whether sensitivity and specificity meet targets established by the WHO for a TB screening
test.
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